Live Breaking News & Updates on National Research Ethics Committee

Stay updated with breaking news from National research ethics committee. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Interim CEO appointed at Galway Chamber

Interim CEO appointed at Galway Chamber
galwaybayfm.ie - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from galwaybayfm.ie Daily Mail and Mail on Sunday newspapers.

Deirdre Mac Loughlin , Galway Chamber Policy Strategy Committee , National Research Ethics Committee , Galway Chamber , Hp International , Mac Loughlin , Data Analytics ,

Acute rehabilitation following traumatic anterior shoulder dislocation (ARTISAN): pragmatic, multicentre, randomised controlled trial

Objective To assess the effects of an additional programme of physiotherapy in adults with a first-time traumatic shoulder dislocation compared with single session of advice, supporting materials, and option to self-refer to physiotherapy.

Design Pragmatic, multicentre, randomised controlled trial (ARTISAN).

Setting and participants Trauma research teams at 41 UK NHS Trust sites screened adults with a first time traumatic anterior shoulder dislocation confirmed radiologically, being managed non-operatively. People were excluded if they presented with both shoulders dislocated, had a neurovascular complication, or were considered for surgical management.

Interventions One session of advice, supporting materials, and option to self-refer to physiotherapy (n=240) was assessed against the same advice and supporting materials and an additional programme of physiotherapy (n=242). Analyses were on an intention-to-treat basis with secondary per protocol analyses.

Ma ....

East Suffolk , United Kingdom , North Yorkshire , West Suffolk , United Kingdom General , Glasgow City , City Of , West Midlands , Henry Nwankwo , Christopher Ratcliffe , Hannah Riley , Nicola Parker , Maria Mestre , Rachel Chester , Alison Armstrong , Rebeccas Kearney , Hannah Craig , Aileen Nacorda , Kathryn Allison , Fiona Carleton , Chandramohan Panneerselvam , Leanne Dymott , David Torgerson , David Bailey , Hayley Potter , Sarah Melling ,

Ireland future-proofing emerging health threats response with new appointment

Ireland future-proofing emerging health threats response with new appointment
euractiv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from euractiv.com Daily Mail and Mail on Sunday newspapers.

Democratic Republic Of The Congo , Stephen Donnelly , Mary Horgan , Breda Smyth , Eu Health Emergency Preparedness Authority , University College Dublin , Public Health Reform Expert Advisory Group , European Medicines Agency , Infectious Diseases Society Of Ireland , European Commission , Health Ministry , National Public Health Emergency Team , European Centre For Disease Prevention , National Research Ethics Committee , Ireland Department Of Health , Health Threats , Professor Mary Horgan , Mater Misericordiae Hospital , Infectious Diseases Society , National Research Ethics , Minister Stephen Donnelly , Chief Medical Officer , European Centre , Disease Prevention , Democratic Republic , Emergency Preparedness Authority ,

Professor Seamus O'Reilly

In this episode, Dr Chris Luke is in conversation with Professor Seamus O'Reilly, Consultant Medical Oncologist and Cork University Hospital, Associate ....

Chris Luke , Seamus Oreilly , Cork University Hospital , Breast International Group , Advisory Council Of The National Cancer Registry , Early Drugs Task , Professor Of Medicine At University College Cork , National Research Ethics Committee , Professor Seamuso Reilly , Consultant Medical Oncologist , Associate Professor , University College Cork , Vice Clinical Lead , Cancer Trials Ireland , Executive Board , Early Drugs Task Force , Advisory Council , National Cancer ,

Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial

Objective To report the efficacy, safety, and exploratory immunogenicity findings of two 5 µg doses of the BIV1-CovIran vaccine.

Design Randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial.

Setting In six cities of Iran, including Bushehr, Isfahan, Karaj, Mashhad, Shiraz, and Tehran. The first vaccine or placebo injection of the first participant was on 16 May 2021 in Tehran. The last vaccine or placebo injection of the last participant occurred on 15 July 2021 in Isfahan.

Participants 20 000 participants aged 18-75 years were randomly assigned to the intervention or placebo groups with a ratio of 2:1.

Intervention 5 µg vaccine or placebo with the interval of 28 days.

Main outcome measures Vaccine efficacy for a 90 day follow-up period, safety and explanatory immunogenicity assessment, and variant detection during the trial.

Results 20 000 participants were recruited and randomly assigned to receive BIV1-CovIr ....

Eteläuomen Läi , Asghar Abdoli , Farzin Khorvash , Shifa Pharmed , Mohammad Reza Malekpour , Hamed Hosseini , Minoo Mohraz , Sahar Saeedi Moghaddam , Maryam Amini Pouya , Katayoun Vahdat , Mohsen Abbasi Kangevari , Mohammadreza Salehi , Mohsen Moghadami , Rozita Khodashahi , Nazila Rezaei , Payam Tabarsi , Erfan Ghasemi , Hassan Jalili , Mohammad Taqavian , Keyvan Koohgir , Akbar Borandegi , Yasaman Ghabdian , Hamidreza Jamshidi , Iranian Research Centre , Amirabad Virology Laboratory , Shifa Pharmed Industrial Group ,